HUP0300772A3 - Medicament for the immunotherapy of malignant tumours - Google Patents

Medicament for the immunotherapy of malignant tumours

Info

Publication number
HUP0300772A3
HUP0300772A3 HU0300772A HUP0300772A HUP0300772A3 HU P0300772 A3 HUP0300772 A3 HU P0300772A3 HU 0300772 A HU0300772 A HU 0300772A HU P0300772 A HUP0300772 A HU P0300772A HU P0300772 A3 HUP0300772 A3 HU P0300772A3
Authority
HU
Hungary
Prior art keywords
immunotherapy
medicament
malignant tumours
tumours
malignant
Prior art date
Application number
HU0300772A
Other languages
English (en)
Original Assignee
Liponova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Ag filed Critical Liponova Ag
Publication of HUP0300772A2 publication Critical patent/HUP0300772A2/hu
Publication of HUP0300772A3 publication Critical patent/HUP0300772A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0300772A 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours HUP0300772A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (2)

Publication Number Publication Date
HUP0300772A2 HUP0300772A2 (en) 2003-08-28
HUP0300772A3 true HUP0300772A3 (en) 2005-11-28

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300772A HUP0300772A3 (en) 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours

Country Status (20)

Country Link
US (2) US20030129206A1 (hu)
EP (1) EP1305041B1 (hu)
JP (1) JP2004505058A (hu)
AT (1) ATE330626T1 (hu)
AU (1) AU2001279775A1 (hu)
BG (1) BG107482A (hu)
CA (1) CA2417374A1 (hu)
CY (1) CY1105179T1 (hu)
CZ (1) CZ299669B6 (hu)
DE (1) DE50110274D1 (hu)
DK (1) DK1305041T3 (hu)
ES (1) ES2267800T3 (hu)
HK (1) HK1055562A1 (hu)
HU (1) HUP0300772A3 (hu)
NO (1) NO20030420L (hu)
PL (1) PL358675A1 (hu)
PT (1) PT1305041E (hu)
SI (1) SI1305041T1 (hu)
SK (1) SK822003A3 (hu)
WO (1) WO2002009745A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
KR20050109498A (ko) * 2003-02-20 2005-11-21 유니버시티 오브 코네티컷 헬스 센터 암 또는 전염병 치료에서 열 충격 단백질 또는알파-2-마크로글로불린을 포함하는 조성물을 사용하는 방법
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
CN102470167A (zh) 2009-07-02 2012-05-23 Ith免疫治疗控股公司 基于外泌体的癌症治疗
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
ES2908885T3 (es) 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
EP1064390A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp IMPROVED ANTI-TUMOR IMMUNITY
CA2326739A1 (en) * 1998-04-02 1999-10-14 The Regents Of The University Of California Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
SI1305041T1 (sl) 2006-12-31
DE50110274D1 (de) 2006-08-03
CY1105179T1 (el) 2010-03-03
PL358675A1 (en) 2004-08-09
EP1305041A1 (de) 2003-05-02
HUP0300772A2 (en) 2003-08-28
JP2004505058A (ja) 2004-02-19
US20030129206A1 (en) 2003-07-10
DK1305041T3 (da) 2006-10-23
NO20030420D0 (no) 2003-01-27
EP1305041B1 (de) 2006-06-21
US20070134275A1 (en) 2007-06-14
BG107482A (bg) 2003-11-28
CZ299669B6 (cs) 2008-10-08
AU2001279775A1 (en) 2002-02-13
HK1055562A1 (en) 2004-01-16
PT1305041E (pt) 2006-09-29
ES2267800T3 (es) 2007-03-16
NO20030420L (no) 2003-01-27
CZ2003179A3 (cs) 2004-01-14
WO2002009745A1 (de) 2002-02-07
ATE330626T1 (de) 2006-07-15
SK822003A3 (en) 2004-05-04
CA2417374A1 (en) 2003-01-27

Similar Documents

Publication Publication Date Title
PL354540A1 (en) Drugs for the treatment of malignant tumours
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
HK1083771A1 (en) Anti-neovasculature preparations for cancer
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
GB9927328D0 (en) Immunotherapy
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
IL148579A0 (en) Oncolytic combinations for the treatment of cancer
EP1462456A4 (en) TUMOR ANTIGENS
AU2001263383A1 (en) Use of pyridinylimidazole carbamate derivate for the manufacture of a medicament for the treatment of cancer
GB0228900D0 (en) Cancer Immunotherapy
AU8322401A (en) Indole compounds useful for the treatment of cancer
PL356770A1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
HUP0300772A3 (en) Medicament for the immunotherapy of malignant tumours
AU2152102A (en) Immunotherapeutic combinations for the treatment of tumors
AU2002221521A1 (en) Immunotherapeutic combinations for the treatment of tumors
EP1496923A4 (en) IMMUNOTHERAPY AGAINST CANCER
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2002236517A1 (en) Targetet retoviral vectors for cancer immunotherapy
HK1058623A1 (en) A combination comprising camptothecin and a stilbene derivative for the treatment of cancer.
AU2002304883A1 (en) Device for the treatment of tumours
AU2002249221A1 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: LIPONOVA AG, DE

Free format text: FORMER OWNER(S): LIPONOVA GMBH., DE

FD9A Lapse of provisional protection due to non-payment of fees